BIOMOLECULAR, GENETIC AND PATHOLOGIC FEATURES OF CARDIA CANCER
Paolo Dellabona, Sheila Krishnadath
The role of macrophages in solid tumors development
Michele De Palma
EGJ cancer: is there a molecular border?
Cardia cancer: is it still useful to maintain a separate classification between esophageal and gastric neoplasia?
Which is the clinical impact of CTC and circulating DNA in real clinical life? And tomorrow?
“The ecstasy and agony” of predictive biomarkers in current personalized medicine
Optimization of molecular-guided therapies in metastatic EGJ cancer
Why do I bust my balls every day on these issues? The perspective of a young oncological surgeon
ONCOLOGICAL FEATURES IN EGJ CANCER
Henk Hartgrink, Sheila Krishnadath
May radiomics play a role in diagnostic, staging and re-staging of cardia cancer?
Perioperative chemotherapy or chemoradiotherapy in junctional cancer
Is microsatellite instability a criterion of choice for perioperative chemotherapy?
Immunotherapy of cardia cancer: which is the real clinical impact?
Adjuvant chemoterapy in the era of ct-DNA
Molecular-based patient selection and treatment in cardia cancer
Drop out of fragile patient during neoadjuvant treatment: what we should do?
Pushing the borders of stage IV: do target therapies and immunotherapy really change treatment strategies?
Jan Van Lanschot